Several multiplex immunoassay studies identified elevated insulin-related peptides in untreated first-onset schizophrenia subjects, suggesting that dysregulation of glucose metabolic pathways may have a role in the development of schizophrenia (Guest et al., 2010, 2011; Schwarz et al., 2012c). This evidence concerns the gene INS and schizophrenia.